Alnylam Pharmaceuticals, Inc. (ALNY)
286.98
-6.47
(-2.20%)
USD |
NASDAQ |
May 15, 16:00
286.73
-0.25
(-0.09%)
After-Hours: 20:00
Alnylam Pharmaceuticals EPS Diluted (Quarterly) : 1.508 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Aldeyra Therapeutics, Inc. | -0.0572 |
| Ionis Pharmaceuticals, Inc. | -0.5612 |
| Gilead Sciences, Inc. | 1.612 |
| Regeneron Pharmaceuticals, Inc. | 6.752 |
| Sarepta Therapeutics, Inc. | 2.878 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 205.99M |
| Revenue (Quarterly) | 1.167B |
| Total Expenses (Quarterly) | 961.18M |
| Enterprise Value | 38.28B |
| Gross Profit Margin (Quarterly) | 81.91% |
| Profit Margin (Quarterly) | 17.65% |
| Earnings Yield | 1.47% |
| Operating Earnings Yield | 1.93% |
| Normalized Earnings Yield | 1.437 |